Evaxion A/S (EVAX) News Today $6.29 +0.57 (+9.97%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.25 -0.04 (-0.57%) As of 10/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Evaxion expands AI-Immunology™ platform with automated vaccine design moduleOctober 8 at 5:31 PM | finance.yahoo.comEvaxion expands AI-Immunologyâ„¢ platform with automated vaccine design moduleOctober 8 at 8:18 AM | globenewswire.comEvaxion to Present New Data on AI-Designed Cancer Vaccine at SITC 2025October 6 at 1:27 PM | msn.comEvaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual MeetingOctober 3, 2025 | globenewswire.comEvaxion A (EVAX) Price Target Increased by 10.00% to 11.22October 1, 2025 | msn.comEvaxion Biotech Shares Jump Following MSD Vaccine Licensing DealSeptember 26, 2025 | msn.comEvaxion Biotech price target raised to $16 from $14 at H.C. WainwrightSeptember 25, 2025 | msn.comEvaxion Rises After Licensing Vaccine Candidate to Merck & Co.September 25, 2025 | marketwatch.comMSD pays up to nearly $600m for Evaxion’s mystery vaccine candidateSeptember 25, 2025 | finance.yahoo.comEvaxion A/S - Special CallSeptember 25, 2025 | seekingalpha.comEvaxion Licenses EVX-B3 Vaccine Candidate to MerckSeptember 25, 2025 | marketwatch.comEvaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What HappenedSeptember 25, 2025 | msn.comEvaxion Biotech stock soars after MSD licenses its vaccine candidateSeptember 25, 2025 | za.investing.comMerck in-licenses Evaxion vaccine candidate in a deal worth up to $600MSeptember 25, 2025 | msn.comEvaxion out-licenses vaccine candidate EVX-B3 to MSDSeptember 25, 2025 | globenewswire.comEvaxion to present at several conferences during the second half of 2025August 27, 2025 | markets.businessinsider.comEvaxion Biotech A/S (NASDAQ:EVAX) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | msn.comEvaxion A/S (EVAX) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.comEvaxion Biotech Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comInsights Ahead: Evaxion Biotech's Quarterly EarningsAugust 14, 2025 | benzinga.comEvaxion announces business update and second quarter 2025 financial resultsAugust 14, 2025 | finance.yahoo.comEvaxion A/S Reports Q2 2025 Financials and Strategic ProgressAugust 14, 2025 | msn.comEvaxion to announce business update and second quarter 2025 financial results on August 14, 2025August 11, 2025 | globenewswire.comEvaxion A/S Announces Executive Changes to Boost AI-Immunology PlatformJuly 30, 2025 | theglobeandmail.comEvaxion to present two-year clinical efficacy data from Phase 2 EVX-01 trialJuly 25, 2025 | msn.comEvaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025July 25, 2025 | globenewswire.comEvaxion finalizes agreement with EIB to convert debt into equityJuly 11, 2025 | globenewswire.comEvaxion CEO Departs; CFO and Interim CEO AppointedJuly 1, 2025 | marketwatch.comEvaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolioJuly 1, 2025 | globenewswire.comEvaxion A/S Launches EVX-B4 Vaccine Development Program Targeting Group A Streptococcus InfectionsJune 27, 2025 | nasdaq.comEvaxion A/S (EVAX) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comEVAX AI Technology Produces New Vaccine CandidateJune 25, 2025 | msn.comEvaxion expands R&D pipeline with new vaccine program targeting Group A StreptococcusJune 25, 2025 | globenewswire.comEvaxion Biotech Receives Grant Funding to Develop New Polio VaccineJune 4, 2025 | msn.comEvaxion receives grant funding to design new polio vaccineJune 3, 2025 | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) Q1 2025 Earnings Call TranscriptMay 29, 2025 | msn.comEvaxion Biotech’s Earnings Call Highlights Progress and ChallengesMay 29, 2025 | msn.comEvaxion Biotech Reports Q1 2025 Progress and FinancialsMay 27, 2025 | tipranks.comEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptMay 27, 2025 | seekingalpha.comEvaxion Biotech: Evaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | finanznachrichten.deEvaxion announces business update and first quarter 2025 financial resultsMay 27, 2025 | globenewswire.comA Look at Evaxion Biotech's Upcoming Earnings ReportMay 26, 2025 | benzinga.comEvaxion Biotech: Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025May 25, 2025 | finanznachrichten.deEvaxion A/S to Host Conference Call for Q1 2025 Financial Results and Business Update on May 27, 2025May 25, 2025 | nasdaq.comEvaxion at Sidoti Conference: AI-Driven Drug Development StrategyMay 23, 2025 | investing.comEvaxion to announce business update and first quarter 2025 financial results on May 27, 2025May 23, 2025 | globenewswire.comEvaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01May 22, 2025 | globenewswire.comEvaxion A/S ADRMay 21, 2025 | wsj.comEvaxion Biotech A/S Announces Key Resolutions from April 2025 AGMMay 5, 2025 | tipranks.comEvaxion Reports Positive Data For Vaccine Candidate EVX-01April 30, 2025 | nasdaq.com Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVAX Media Mentions By Week EVAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼-0.190.63▲Average Medical News Sentiment EVAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼42▲EVAX Articles Average Week Get the Latest News and Ratings for EVAX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Evaxion A/S and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Neuphoria Therapeutics News Today Hoth Therapeutics News Today Clearside Biomedical News Today Cingulate News Today Apollomics News Today Citius Pharmaceuticals News Today ProPhase Labs News Today Lexaria Bioscience News Today Abpro News Today Natural Alternatives International News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVAX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
